Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Brain Citrullination Patterns and T Cell Reactivity of Cerebrospinal Fluid-Derived CD4+ T Cells in Multiple Sclerosis.

Faigle W, Cruciani C, Wolski W, Roschitzki B, Puthenparampil M, Tomas-Ojer P, Sellés-Moreno C, Zeis T, Jelcic I, Schaeren-Wiemers N, Sospedra M, Martin R.

Front Immunol. 2019 Apr 10;10:540. doi: 10.3389/fimmu.2019.00540. eCollection 2019.

2.

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R.

Cell. 2018 Sep 20;175(1):85-100.e23. doi: 10.1016/j.cell.2018.08.011. Epub 2018 Aug 30.

3.

Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.

Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, Reindl M, Weller M, Martin R, Lutterotti A, Schippling S.

J Neuroophthalmol. 2019 Mar;39(1):3-7. doi: 10.1097/WNO.0000000000000669.

PMID:
30015656
4.

Phenotypic and functional complexity of brain-infiltrating T cells in Rasmussen encephalitis.

Al Nimer F, Jelcic I, Kempf C, Pieper T, Budka H, Sospedra M, Martin R.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 8;5(1):e419. doi: 10.1212/NXI.0000000000000419. eCollection 2018 Jan.

5.

Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy - a realistic possibility?

Jelcic I, Combaluzier B, Jelcic I, Sospedra M, Grimm J, Martin R.

Swiss Med Wkly. 2017 Oct 31;147:w14520. doi: 10.4414/smw.2017.14520. eCollection 2017.

6.

Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.

Jelcic I, Jelcic I, Kempf C, Largey F, Planas R, Schippling S, Budka H, Sospedra M, Martin R.

Ann Neurol. 2016 Mar;79(3):404-18. doi: 10.1002/ana.24574. Epub 2016 Feb 13.

7.

Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions.

Planas R, Metz I, Ortiz Y, Vilarrasa N, Jelčić I, Salinas-Riester G, Heesen C, Brück W, Martin R, Sospedra M.

Ann Clin Transl Neurol. 2015 Sep;2(9):875-93. doi: 10.1002/acn3.218. Epub 2015 Jun 8.

8.

Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.

Jelcic I, Combaluzier B, Jelcic I, Faigle W, Senn L, Reinhart BJ, Ströh L, Nitsch RM, Stehle T, Sospedra M, Grimm J, Martin R.

Sci Transl Med. 2015 Sep 23;7(306):306ra150. doi: 10.1126/scitranslmed.aac8691. Epub 2015 Sep 23.

9.

Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.

Pfender N, Jelcic I, Linnebank M, Schwarz U, Martin R.

Neurology. 2015 Jun 9;84(23):2377-8. doi: 10.1212/WNL.0000000000001659. Epub 2015 May 8. No abstract available.

10.

Immunology of progressive multifocal leukoencephalopathy.

Jelcic I, Jelcic I, Faigle W, Sospedra M, Martin R.

J Neurovirol. 2015 Dec;21(6):614-22. doi: 10.1007/s13365-014-0294-y. Epub 2015 Mar 5. Review.

11.

Whole Genome Sequencing Reveals a Chromosome 9p Deletion Causing DOCK8 Deficiency in an Adult Diagnosed with Hyper IgE Syndrome Who Developed Progressive Multifocal Leukoencephalopathy.

Day-Williams AG, Sun C, Jelcic I, McLaughlin H, Harris T, Martin R, Carulli JP.

J Clin Immunol. 2015 Jan;35(1):92-6. doi: 10.1007/s10875-014-0114-4. Epub 2014 Nov 12.

12.

Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

Sospedra M, Schippling S, Yousef S, Jelcic I, Bofill-Mas S, Planas R, Stellmann JP, Demina V, Cinque P, Garcea R, Croughs T, Girones R, Martin R.

Clin Infect Dis. 2014 Dec 1;59(11):1588-92. doi: 10.1093/cid/ciu682. Epub 2014 Sep 11.

13.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

14.

JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment.

Schippling S, Kempf C, Büchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, Weller M, Budka H, Martin R.

Ann Neurol. 2013 Oct;74(4):622-6. doi: 10.1002/ana.23973. Epub 2013 Sep 16.

PMID:
23868420
15.

Primary blood neutrophils express a functional cell surface Toll-like receptor 9.

Lindau D, Mussard J, Wagner BJ, Ribon M, Rönnefarth VM, Quettier M, Jelcic I, Boissier MC, Rammensee HG, Decker P.

Eur J Immunol. 2013 Aug;43(8):2101-13. doi: 10.1002/eji.201142143.

16.

T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors.

Jelcic I, Aly L, Binder TM, Jelcic I, Bofill-Mas S, Planas R, Demina V, Eiermann TH, Weber T, Girones R, Sospedra M, Martin R.

J Virol. 2013 Mar;87(6):3393-408. doi: 10.1128/JVI.02803-12. Epub 2013 Jan 9.

17.

Multifocal CNS demyelination after octreotide treatment for metastatic meningioma.

Schreglmann SR, Jelčić I, Taegtmeyer AB, Linnebank M, Weller M.

Clin Neurol Neurosurg. 2013 Jun;115(6):817-9. doi: 10.1016/j.clineuro.2012.07.021. Epub 2012 Aug 5. No abstract available.

PMID:
22874886
18.

Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.

Kallweit U, Jelcic I, Braun N, Fischer H, Zörner B, Schreiner B, Sokolov AA, Martin R, Weller M, Linnebank M.

Clin Neuropharmacol. 2012 Mar-Apr;35(2):77-80. doi: 10.1097/WNF.0b013e31824644e6.

19.

No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients.

Lutterotti A, Jelcić I, Schulze C, Schippling S, Breiden P, Mazzanti B, Reinhardt S, DiGioia M, Repice A, Massacesi L, Sputtek A, Salinas-Riester G, Kroeger N, Sospedra M, Saccardi R, Zander A, Martin R.

Mult Scler. 2012 Aug;18(8):1188-92. doi: 10.1177/1352458511434067. Epub 2012 Jan 17.

PMID:
22252466
20.

Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis.

Jelcić I, Hsu KC, Kakalacheva K, Breiden P, Dupont B, Uhrberg M, Martin R, Münz C, Lünemann JD.

Mult Scler. 2012 Jul;18(7):951-8. doi: 10.1177/1352458511431726. Epub 2011 Dec 20.

PMID:
22185807
21.

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.

Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.

Eur J Immunol. 2012 Mar;42(3):790-8. doi: 10.1002/eji.201142108. Epub 2011 Dec 27.

22.

Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.

Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R.

Brain. 2011 Sep;134(Pt 9):2687-702. doi: 10.1093/brain/awr206.

PMID:
21908874
23.

Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.

Conzett KB, Kolm I, Jelcic I, Kamarachev J, Dummer R, Braun R, French LE, Linnebank M, Hofbauer GF.

Arch Dermatol. 2011 Aug;147(8):991-2. doi: 10.1001/archdermatol.2011.212. No abstract available.

PMID:
21844470
24.

The polymorphic HCMV glycoprotein UL20 is targeted for lysosomal degradation by multiple cytoplasmic dileucine motifs.

Jelcic I, Reichel J, Schlude C, Treutler E, Sinzger C, Steinle A.

Traffic. 2011 Oct;12(10):1444-56. doi: 10.1111/j.1600-0854.2011.01236.x. Epub 2011 Jul 12.

25.

The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is a possible risk factor for amyotrophic lateral sclerosis.

Kühnlein P, Jung H, Farkas M, Keskitalo S, Ineichen B, Jelcic I, Petersen J, Semmler A, Weller M, Ludolph AC, Linnebank M.

Amyotroph Lateral Scler. 2011 Mar;12(2):136-9. doi: 10.3109/17482968.2010.536985. Epub 2010 Dec 6.

26.

Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.

Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lünemann JD.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4788-92. doi: 10.1073/pnas.0807319106. Epub 2009 Mar 4. Erratum in: Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4336.

27.

EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.

Lünemann JD, Jelcić I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Münz C.

J Exp Med. 2008 Aug 4;205(8):1763-73. doi: 10.1084/jem.20072397. Epub 2008 Jul 28.

28.
29.
30.

Study of some immunological parameters in workers occupationally exposed to benzene.

Bogadi-Sare A, Zavalic M, Trosić I, Turk R, Kontosić I, Jelcić I.

Int Arch Occup Environ Health. 2000 Aug;73(6):397-400.

PMID:
11007343
31.

[Specificity of diagnostic procedures in occupational diseases].

Bogadi-Sare A, Zavalić M, Mustajbegović J, Zuskin E, Jelcić I, Brumen V.

Lijec Vjesn. 2000 Jan-Feb;122(1-2):17-20. Review. Croatian.

PMID:
10916352
32.

[Occupational medicine worldwide and in Croatia].

Zuskin E, Sarić M, Mustajbegović J, Decković-Vukres V, Milković-Kraus S, Jelcić I.

Lijec Vjesn. 1999 Mar;121(3):63-9. Croatian.

PMID:
10437343
33.

[Improper body posture of bus drivers].

Jelcić I.

Arh Hig Rada Toksikol. 1995 Mar;46(1):89-93. Croatian.

PMID:
7575150
34.

[Respiratory symptoms and pulmonary ventilating capacity in professional drivers and mechanics].

Zuskin E, Mustajbegović J, Jelcić I, Kern J, Ivanković D.

Arh Hig Rada Toksikol. 1992 Jun;43(2):165-74. Croatian.

PMID:
1417501
35.
36.

[Eye injuries in traffic accident traumatology].

Katusić D, Ledić I, Sikić J, Jelcić I.

Acta Med Iugosl. 1989;43(5):405-8. Croatian.

PMID:
2626975
37.

Detection of preosteoarthrotic condition of the knee joint in professional drivers with 99mTc-polyphosphate.

Jajić I, Jelcić I, Schwarzwald M, Delimar N.

Acta Med Iugosl. 1976;30(3):295-305. No abstract available.

PMID:
952241
38.

[Trends in traffic injuries in the Serbian Federal Republic of Yugoslavia].

Jelcić I.

Nar Zdrav. 1974 Sep-Oct;30(9-10):231-6. Serbian. No abstract available.

PMID:
4469024
39.

[Increased mortality on the roads of Yugoslavia].

Jelcić I.

Lijec Vjesn. 1973 Aug;95(8):433-7. Croatian. No abstract available.

PMID:
4750525

Supplemental Content

Loading ...
Support Center